MGCD265 is an orally administered receptor tyrosine kinase inhibitor that targets MET and other receptors. This study is a Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) that has activating genetic changes of the MET gene (mutation or amplification [increase number of gene copies]). Testing for tumor gene changes can be performed in tumor tissue or blood samples. Patients must have previously received treatment with chemotherapy. The number of patients to be enrolled will depend on how many enrolled patients experience tumor size reduction. MGCD265 will be administered orally, twice daily. The study is designed to evaluate whether the number of patients experiencing tumor size reduction is substantially higher than would be expected with other available treatments.
Phase 2, Parallel-Arm Study of MGCD265 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor
If testing has not already been performed, the study will provide for the testing.
Non-Small Cell Lung CancerMiratiMGCD265METNSCLC
You can join if…
Open to people ages 18 years and up
Diagnosis of non-small cell lung cancer
Metastatic or locally advanced disease
Prior platinum chemotherapy or immunotherapy
Test result showing genetic change in MET tumor gene
At least one tumor that can be measured on a radiographic scan
You CAN'T join if...
Prior treatment with inhibitor of MET or HGF
Prior positive test for EGFR mutation or ALK gene rearrangement
Uncontrolled tumor in the brain
University of California, San Franciscoaccepting new patients San Francisco, California, 94143, USA
Providence Saint Joseph Medical Centeraccepting new patients Burbank, California, 91505, USA
Saint Joseph Heritage Healthcareaccepting new patients Fullerton, California, 92835, USA
University of California San Diegoaccepting new patients La Jolla, California, 92121, USA
Loma Linda University Medical Centeraccepting new patients Loma Linda, California, 92354, USA
Innovative Clinical Reseach Instituteaccepting new patients Whittier, California, 90603, USA